SCHEMBL7032058

SCHEMBL7032058

Cn1c(=O)n(Cc2ccccc2)c(=O)c2sc(C(=O)OCc3ccccc3)cc21

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.53
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
PKM P14618 2/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
KDM4E B2RXH2 1/20 0.42
HPD P32754 2/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
HTT P42858 1/20 0.40
HPGD P15428 1/20 0.40
PARG Q86W56 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7033357 0.89 SMN1; SMN2 (0.54) MMP13TSHRSMN1; SMN2PKMRAB9A
SCHEMBL7035477 0.85 MMP13 (0.51) MMP13TSHRHSD17B10SMN1; SMN2PKM
SCHEMBL6252686 0.83 MMP13 (0.53) MMP13TSHRHSD17B10SMN1; SMN2PKM
SCHEMBL7033633 0.81 TRPA1 (0.57) HSD17B10SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL6730796 0.79 MMP13 (0.49) MMP13TSHRHSD17B10SMN1; SMN2KMT2A
SCHEMBL6533924 0.79 MMP13 (0.49) MMP13TSHRHSD17B10SMN1; SMN2PKM
SCHEMBL6470802 0.79 TRPA1 (0.48) MMP13TSHRHSD17B10SMN1; SMN2KMT2A
SCHEMBL6724753 0.79 MMP13 (0.48) MMP13TSHRHSD17B10RAB9AKMT2A
SCHEMBL6476942 0.79 MMP13 (0.48) MMP13KMT2AMEN1LMNA
SCHEMBL6258183 0.79 MMP13 (0.48) MMP13TSHRHSD17B10RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 MMP13 1/4885TSHR 3353/4885HSD17B10 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.